Abstract
Malaria sexual stage and mosquito transmission-blocking vaccines (SSM-TBV) have recently gained prominence as a necessary tool for malaria eradication. SSM-TBVs are unique in that, with the exception of parasite gametocyte antigens, they primarily target parasite or mosquito midgut surface antigens expressed only inside the mosquito. As such, the primary perceived limitation of SSM-TBVs is that the absence of natural boosting following immunization will limit its efficacy, since the antigens are never presented to the human immune system. An ideal, safe SSM-TBV formulation must overcome this limitation. We provide a focused evaluation of relevant nano-/microparticle technologies that can be applied toward the development of leading SSM-TBV candidates, and data from a proof-of-concept study demonstrating that a single inoculation and controlled release of antigen in mice, can elicit long-lasting protective antibody titers. We conclude by identifying the remaining critical gaps in knowledge and opportunities for moving SSM-TBVs to the field.
Keywords: Antigen, controlled release, immunity, malaria, midgut, mosquito, nanotechnology, natural boosting, sexual stages, transmission-blocking vaccine
Current Molecular Medicine
Title:Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response
Volume: 13 Issue: 4
Author(s): R.R. Dinglasan, J.S. Armistead, J.F. Nyland, X. Jiang and H.Q. Mao
Affiliation:
Keywords: Antigen, controlled release, immunity, malaria, midgut, mosquito, nanotechnology, natural boosting, sexual stages, transmission-blocking vaccine
Abstract: Malaria sexual stage and mosquito transmission-blocking vaccines (SSM-TBV) have recently gained prominence as a necessary tool for malaria eradication. SSM-TBVs are unique in that, with the exception of parasite gametocyte antigens, they primarily target parasite or mosquito midgut surface antigens expressed only inside the mosquito. As such, the primary perceived limitation of SSM-TBVs is that the absence of natural boosting following immunization will limit its efficacy, since the antigens are never presented to the human immune system. An ideal, safe SSM-TBV formulation must overcome this limitation. We provide a focused evaluation of relevant nano-/microparticle technologies that can be applied toward the development of leading SSM-TBV candidates, and data from a proof-of-concept study demonstrating that a single inoculation and controlled release of antigen in mice, can elicit long-lasting protective antibody titers. We conclude by identifying the remaining critical gaps in knowledge and opportunities for moving SSM-TBVs to the field.
Export Options
About this article
Cite this article as:
Dinglasan R.R., Armistead J.S., Nyland J.F., Jiang X. and Mao H.Q., Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040002
DOI https://dx.doi.org/10.2174/1566524011313040002 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Administration of Drug and Nutritional Components in Nano-Engineered Form to Increase Delivery Ratio and Reduce Current Inefficient Practice
Recent Patents on Drug Delivery & Formulation Drug Eluting Stents and Beyond
Current Pharmaceutical Design Biosafety of Onco-Retroviral Vectors
Current Gene Therapy Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity
Current Medicinal Chemistry Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets Understanding Adverse Drug Reactions and Drug Allergies: Principles, Diagnosis and Treatment Aspects
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances and Perceptions in Studies of Heterodimerization between G Protein-Coupled Receptors
Protein & Peptide Letters COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Current Pharmaceutical Design Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Immunosuppression in Liver Transplantation
Current Drug Targets Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews The MRP Family and Anticancer Drug Metabolism
Current Drug Metabolism Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Searching Drug-Like Anti-cancer Compound(s) Based on G-Quadruplex Ligands
Current Pharmaceutical Design Virus Diagnostics on Microarrays
Current Pharmaceutical Biotechnology Allosteric Inhibition of the Hepatitis C Virus NS5B RNA Dependent RNA Polymerase
Infectious Disorders - Drug Targets Immunophenotype of Vitamin D Receptor Polymorphism Associated to Risk of HIV-1 Infection and Rate of Disease Progression
Current HIV Research Recent Advances in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology